To confirm the hypothesis that Cdk4 deficiency enhances anti-tumor immunity in vivo through the activation of type I interferon pathway, control and Cdk4−/− MCA205 cells were subcutaneously transplanted into Ifnar1−/− (Interferon-alpha/beta receptor) mice. This evidence concerns the gene CDK4 and neoplasm.